| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Breast Neoplasms | 41 | 2021 | 3633 | 5.14 | Why? |
| Neoplasms | 35 | 2021 | 17251 | 2.51 | Why? |
| Antineoplastic Agents | 17 | 2020 | 3550 | 2.48 | Why? |
| Receptor, ErbB-2 | 13 | 2020 | 267 | 2.42 | Why? |
| Triple Negative Breast Neoplasms | 5 | 2019 | 92 | 2.39 | Why? |
| Trastuzumab | 10 | 2020 | 108 | 2.15 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2019 | 1573 | 1.67 | Why? |
| Biomarkers, Tumor | 8 | 2019 | 1314 | 1.50 | Why? |
| Biosimilar Pharmaceuticals | 4 | 2019 | 205 | 1.47 | Why? |
| Aminopyridines | 3 | 2018 | 121 | 1.44 | Why? |
| Medical Oncology | 11 | 2021 | 3826 | 1.41 | Why? |
| Neoadjuvant Therapy | 9 | 2021 | 554 | 1.40 | Why? |
| Antineoplastic Agents, Immunological | 7 | 2019 | 830 | 1.34 | Why? |
| Cyclin-Dependent Kinase 6 | 4 | 2019 | 43 | 1.28 | Why? |
| Cyclin-Dependent Kinase 4 | 4 | 2019 | 44 | 1.27 | Why? |
| Lymphocytes, Tumor-Infiltrating | 4 | 2019 | 130 | 1.19 | Why? |
| Purines | 4 | 2019 | 816 | 1.14 | Why? |
| Chemotherapy, Adjuvant | 9 | 2019 | 606 | 0.97 | Why? |
| Tumor Microenvironment | 3 | 2018 | 264 | 0.92 | Why? |
| Mastectomy, Segmental | 2 | 2018 | 124 | 0.89 | Why? |
| Molecular Targeted Therapy | 8 | 2019 | 1579 | 0.88 | Why? |
| Carcinoma, Ductal, Breast | 3 | 2019 | 149 | 0.88 | Why? |
| Histone Deacetylase Inhibitors | 2 | 2018 | 79 | 0.88 | Why? |
| Precision Medicine | 4 | 2019 | 1477 | 0.87 | Why? |
| Triptorelin Pamoate | 1 | 2019 | 7 | 0.83 | Why? |
| Antineoplastic Agents, Hormonal | 2 | 2019 | 203 | 0.82 | Why? |
| Cancer Vaccines | 2 | 2019 | 136 | 0.82 | Why? |
| CTLA-4 Antigen | 4 | 2019 | 282 | 0.81 | Why? |
| Homologous Recombination | 1 | 2019 | 32 | 0.78 | Why? |
| Inflammatory Breast Neoplasms | 1 | 2018 | 1 | 0.77 | Why? |
| BRCA2 Protein | 1 | 2019 | 82 | 0.76 | Why? |
| BRCA1 Protein | 1 | 2019 | 102 | 0.74 | Why? |
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2017 | 98 | 0.74 | Why? |
| Cetuximab | 1 | 2018 | 35 | 0.73 | Why? |
| Neoplasm Metastasis | 4 | 2018 | 682 | 0.73 | Why? |
| Clinical Trials, Phase I as Topic | 1 | 2020 | 242 | 0.72 | Why? |
| Filgrastim | 1 | 2017 | 25 | 0.71 | Why? |
| Estrogen Receptor alpha | 1 | 2018 | 40 | 0.71 | Why? |
| Antigens, Neoplasm | 2 | 2019 | 230 | 0.70 | Why? |
| DNA Mismatch Repair | 1 | 2017 | 25 | 0.70 | Why? |
| B7-H1 Antigen | 4 | 2020 | 541 | 0.70 | Why? |
| Receptors, Notch | 1 | 2017 | 59 | 0.70 | Why? |
| Genomic Instability | 1 | 2018 | 80 | 0.70 | Why? |
| DNA Repair | 1 | 2018 | 114 | 0.69 | Why? |
| Pyridines | 3 | 2018 | 680 | 0.67 | Why? |
| DNA, Neoplasm | 1 | 2017 | 56 | 0.66 | Why? |
| Thoracic Diseases | 1 | 2018 | 118 | 0.66 | Why? |
| Immunotherapy | 7 | 2019 | 2421 | 0.66 | Why? |
| Neoplastic Cells, Circulating | 1 | 2017 | 68 | 0.63 | Why? |
| Vaccines, Subunit | 2 | 2021 | 1088 | 0.63 | Why? |
| Breast | 3 | 2018 | 290 | 0.62 | Why? |
| DNA Damage | 1 | 2018 | 285 | 0.59 | Why? |
| Carcinoma | 1 | 2018 | 256 | 0.59 | Why? |
| Pyridinium Compounds | 1 | 2014 | 19 | 0.58 | Why? |
| Protein Kinase Inhibitors | 5 | 2020 | 1585 | 0.58 | Why? |
| Lymph Node Excision | 1 | 2017 | 362 | 0.56 | Why? |
| Carcinoma, Non-Small-Cell Lung | 4 | 2019 | 896 | 0.56 | Why? |
| Benzamides | 1 | 2017 | 421 | 0.55 | Why? |
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 77 | 0.55 | Why? |
| Data Interpretation, Statistical | 1 | 2018 | 657 | 0.54 | Why? |
| Thiazoles | 1 | 2018 | 496 | 0.51 | Why? |
| European Union | 1 | 2017 | 565 | 0.51 | Why? |
| Polyethylene Glycols | 1 | 2017 | 574 | 0.50 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.49 | Why? |
| Oncologists | 2 | 2020 | 877 | 0.47 | Why? |
| Patient Care | 2 | 2020 | 1664 | 0.46 | Why? |
| Lung Neoplasms | 4 | 2018 | 3228 | 0.45 | Why? |
| Drug Resistance, Neoplasm | 5 | 2019 | 447 | 0.45 | Why? |
| Anthracyclines | 4 | 2020 | 65 | 0.44 | Why? |
| Genital Neoplasms, Female | 1 | 2018 | 718 | 0.43 | Why? |
| Patient Selection | 4 | 2021 | 4560 | 0.40 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 3633 | 0.39 | Why? |
| Genomics | 2 | 2018 | 3118 | 0.39 | Why? |
| Humans | 91 | 2021 | 930598 | 0.39 | Why? |
| Drug Delivery Systems | 1 | 2019 | 1365 | 0.38 | Why? |
| Neoplasm Staging | 5 | 2019 | 1999 | 0.37 | Why? |
| Biopsy | 2 | 2017 | 2811 | 0.36 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.36 | Why? |
| Clinical Trials, Phase III as Topic | 4 | 2019 | 782 | 0.36 | Why? |
| Enzyme Inhibitors | 1 | 2019 | 1881 | 0.35 | Why? |
| Drug Design | 2 | 2018 | 2627 | 0.35 | Why? |
| Fertility Preservation | 2 | 2019 | 121 | 0.34 | Why? |
| Half-Life | 2 | 2018 | 298 | 0.33 | Why? |
| Consensus | 2 | 2020 | 6345 | 0.31 | Why? |
| Betacoronavirus | 16 | 2020 | 204454 | 0.30 | Why? |
| Disease-Free Survival | 4 | 2017 | 1654 | 0.29 | Why? |
| Randomized Controlled Trials as Topic | 9 | 2020 | 10649 | 0.28 | Why? |
| Benzimidazoles | 2 | 2018 | 275 | 0.28 | Why? |
| Pneumonia, Viral | 16 | 2020 | 243684 | 0.28 | Why? |
| Societies, Medical | 2 | 2020 | 6907 | 0.28 | Why? |
| Coronavirus Infections | 16 | 2020 | 253789 | 0.28 | Why? |
| Female | 42 | 2021 | 380317 | 0.26 | Why? |
| Clinical Trials as Topic | 7 | 2021 | 7330 | 0.26 | Why? |
| Decision Making | 1 | 2018 | 3132 | 0.26 | Why? |
| Drug Discovery | 1 | 2018 | 3092 | 0.26 | Why? |
| Gastrointestinal Diseases | 1 | 2018 | 2580 | 0.25 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.25 | Why? |
| Liver Diseases | 1 | 2018 | 2698 | 0.24 | Why? |
| Mastectomy | 2 | 2017 | 536 | 0.24 | Why? |
| Quinazolines | 2 | 2017 | 126 | 0.23 | Why? |
| Epigenesis, Genetic | 2 | 2018 | 711 | 0.23 | Why? |
| ErbB Receptors | 2 | 2018 | 320 | 0.21 | Why? |
| Practice Guidelines as Topic | 4 | 2020 | 15421 | 0.21 | Why? |
| Triage | 1 | 2020 | 7151 | 0.21 | Why? |
| Cardiotoxicity | 3 | 2019 | 365 | 0.20 | Why? |
| Allelic Imbalance | 1 | 2019 | 2 | 0.20 | Why? |
| Drug Approval | 2 | 2021 | 1325 | 0.20 | Why? |
| Loss of Heterozygosity | 1 | 2019 | 14 | 0.20 | Why? |
| Venous Thromboembolism | 1 | 2018 | 4273 | 0.20 | Why? |
| Europe | 8 | 2021 | 12702 | 0.20 | Why? |
| Carcinoma, Lobular | 1 | 2019 | 62 | 0.20 | Why? |
| Breast Implantation | 1 | 2019 | 23 | 0.19 | Why? |
| Cell Cycle Checkpoints | 1 | 2019 | 126 | 0.19 | Why? |
| Lymphoma, Large-Cell, Anaplastic | 1 | 2019 | 24 | 0.19 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.19 | Why? |
| Germ-Line Mutation | 1 | 2019 | 86 | 0.19 | Why? |
| Stromal Cells | 1 | 2019 | 105 | 0.19 | Why? |
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 264 | 0.18 | Why? |
| Neoplasm Invasiveness | 2 | 2019 | 582 | 0.18 | Why? |
| Salts | 1 | 2018 | 44 | 0.18 | Why? |
| Troponin C | 1 | 2018 | 29 | 0.18 | Why? |
| Lymphatic Metastasis | 3 | 2017 | 537 | 0.18 | Why? |
| Breast Implants | 1 | 2019 | 64 | 0.18 | Why? |
| Platinum | 1 | 2018 | 54 | 0.18 | Why? |
| Pregnancy Complications, Neoplastic | 1 | 2019 | 79 | 0.18 | Why? |
| Carboplatin | 1 | 2018 | 76 | 0.18 | Why? |
| Enalapril | 1 | 2018 | 54 | 0.18 | Why? |
| Thoracic Wall | 1 | 2018 | 54 | 0.18 | Why? |
| Tumor Cells, Cultured | 1 | 2018 | 254 | 0.18 | Why? |
| Febrile Neutropenia | 1 | 2020 | 179 | 0.17 | Why? |
| Vaccines, Virus-Like Particle | 1 | 2021 | 312 | 0.17 | Why? |
| Taxoids | 1 | 2017 | 45 | 0.17 | Why? |
| Quinazolinones | 1 | 2019 | 135 | 0.17 | Why? |
| WT1 Proteins | 1 | 2017 | 15 | 0.17 | Why? |
| Bridged-Ring Compounds | 1 | 2017 | 45 | 0.17 | Why? |
| Mutation | 5 | 2018 | 12376 | 0.17 | Why? |
| Microsatellite Instability | 1 | 2017 | 57 | 0.17 | Why? |
| Telomere | 1 | 2019 | 146 | 0.17 | Why? |
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2018 | 121 | 0.16 | Why? |
| Pandemics | 21 | 2021 | 389249 | 0.16 | Why? |
| Radiotherapy, Adjuvant | 1 | 2017 | 180 | 0.16 | Why? |
| Phosphatidylinositol 3-Kinases | 1 | 2019 | 347 | 0.16 | Why? |
| Oncology Service, Hospital | 1 | 2020 | 314 | 0.16 | Why? |
| Animals | 8 | 2019 | 78931 | 0.16 | Why? |
| Axilla | 1 | 2017 | 198 | 0.16 | Why? |
| Infection Control | 5 | 2020 | 23131 | 0.16 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 552 | 0.15 | Why? |
| Cyclophosphamide | 1 | 2018 | 387 | 0.15 | Why? |
| Carcinogenesis | 1 | 2018 | 236 | 0.15 | Why? |
| Bevacizumab | 1 | 2017 | 149 | 0.15 | Why? |
| Endpoint Determination | 1 | 2017 | 344 | 0.15 | Why? |
| Vaccines, Attenuated | 1 | 2021 | 952 | 0.15 | Why? |
| Immunologic Factors | 3 | 2020 | 4206 | 0.14 | Why? |
| Predictive Value of Tests | 3 | 2019 | 9537 | 0.14 | Why? |
| Cyclic N-Oxides | 1 | 2014 | 30 | 0.14 | Why? |
| Programmed Cell Death 1 Receptor | 4 | 2020 | 724 | 0.14 | Why? |
| Indolizines | 1 | 2014 | 41 | 0.14 | Why? |
| Prognosis | 7 | 2020 | 32490 | 0.14 | Why? |
| Cyclin-Dependent Kinases | 1 | 2014 | 124 | 0.14 | Why? |
| Piperazines | 1 | 2017 | 445 | 0.14 | Why? |
| Biomarkers, Pharmacological | 1 | 2015 | 150 | 0.13 | Why? |
| Cardiotonic Agents | 1 | 2017 | 418 | 0.13 | Why? |
| Neoplasm Recurrence, Local | 2 | 2018 | 1063 | 0.13 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.13 | Why? |
| Vaccines, Inactivated | 1 | 2021 | 1562 | 0.13 | Why? |
| Cell Cycle | 1 | 2014 | 329 | 0.13 | Why? |
| Receptors, Progesterone | 1 | 2013 | 76 | 0.13 | Why? |
| Standard of Care | 2 | 2018 | 1297 | 0.12 | Why? |
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1014 | 0.12 | Why? |
| History, 20th Century | 1 | 2018 | 1282 | 0.12 | Why? |
| Surgical Oncology | 1 | 2020 | 923 | 0.12 | Why? |
| Receptors, Estrogen | 1 | 2013 | 171 | 0.12 | Why? |
| Radiation Oncology | 1 | 2020 | 834 | 0.11 | Why? |
| Cell Differentiation | 1 | 2018 | 1338 | 0.11 | Why? |
| Cancer Care Facilities | 1 | 2020 | 1190 | 0.11 | Why? |
| Combined Modality Therapy | 2 | 2018 | 3395 | 0.11 | Why? |
| Treatment Outcome | 11 | 2020 | 51732 | 0.11 | Why? |
| Drug Repositioning | 2 | 2020 | 5683 | 0.11 | Why? |
| Health Priorities | 1 | 2020 | 959 | 0.11 | Why? |
| History, 21st Century | 1 | 2018 | 1849 | 0.11 | Why? |
| Radiologists | 1 | 2017 | 873 | 0.11 | Why? |
| Apoptosis | 2 | 2020 | 2335 | 0.11 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.10 | Why? |
| Antibodies, Monoclonal, Humanized | 4 | 2020 | 9335 | 0.10 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.10 | Why? |
| Ventricular Dysfunction, Left | 1 | 2018 | 993 | 0.10 | Why? |
| Bone Neoplasms | 1 | 2013 | 287 | 0.10 | Why? |
| Risk Assessment | 4 | 2020 | 25439 | 0.09 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.09 | Why? |
| Exanthema | 1 | 2018 | 1097 | 0.09 | Why? |
| Telemedicine | 6 | 2021 | 25032 | 0.09 | Why? |
| Vaccines, Synthetic | 1 | 2021 | 3231 | 0.09 | Why? |
| Gene Expression Profiling | 1 | 2019 | 3788 | 0.09 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.09 | Why? |
| Drug Evaluation, Preclinical | 1 | 2019 | 3347 | 0.09 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.08 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.08 | Why? |
| Diarrhea | 1 | 2019 | 2743 | 0.08 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.08 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.08 | Why? |
| Italy | 3 | 2020 | 38444 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.08 | Why? |
| Patient Care Team | 1 | 2020 | 3556 | 0.07 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 8811 | 0.07 | Why? |
| Risk | 1 | 2018 | 5288 | 0.07 | Why? |
| Disease Progression | 3 | 2019 | 13580 | 0.07 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.07 | Why? |
| Disease Management | 2 | 2020 | 6841 | 0.07 | Why? |
| Vascular Endothelial Growth Factor A | 2 | 2020 | 604 | 0.07 | Why? |
| T-Lymphocytes | 2 | 2020 | 6670 | 0.07 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.06 | Why? |
| Proto-Oncogene Proteins | 1 | 2005 | 340 | 0.06 | Why? |
| Time Factors | 4 | 2019 | 31397 | 0.06 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.06 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.06 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.06 | Why? |
| Aged | 10 | 2020 | 215776 | 0.06 | Why? |
| Reproducibility of Results | 2 | 2017 | 11304 | 0.05 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.05 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.05 | Why? |
| Proteasome Inhibitors | 1 | 2020 | 127 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 5277 | 0.05 | Why? |
| Health Services Accessibility | 2 | 2020 | 10697 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Physicians | 1 | 2019 | 4214 | 0.05 | Why? |
| Administration, Metronomic | 1 | 2018 | 27 | 0.05 | Why? |
| Pneumonia | 1 | 2019 | 5652 | 0.05 | Why? |
| Adult | 12 | 2021 | 244371 | 0.05 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.05 | Why? |
| Inflammation | 2 | 2020 | 13255 | 0.05 | Why? |
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 37 | 0.04 | Why? |
| Cross Infection | 1 | 2020 | 8675 | 0.04 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.04 | Why? |
| Bisoprolol | 1 | 2017 | 65 | 0.04 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.04 | Why? |
| International Cooperation | 2 | 2020 | 3436 | 0.04 | Why? |
| Global Burden of Disease | 1 | 2020 | 531 | 0.04 | Why? |
| Ramipril | 1 | 2017 | 81 | 0.04 | Why? |
| Injection Site Reaction | 1 | 2017 | 124 | 0.04 | Why? |
| Prosthesis Design | 1 | 2019 | 594 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Survival Rate | 2 | 2020 | 9206 | 0.04 | Why? |
| Latin America | 1 | 2021 | 1721 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2017 | 647 | 0.04 | Why? |
| Radiotherapy | 1 | 2020 | 608 | 0.04 | Why? |
| Observer Variation | 1 | 2017 | 622 | 0.04 | Why? |
| Geography | 1 | 2021 | 1801 | 0.03 | Why? |
| Fertility | 1 | 2019 | 367 | 0.03 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Cross-Over Studies | 1 | 2017 | 867 | 0.03 | Why? |
| Mammography | 1 | 2017 | 410 | 0.03 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2017 | 801 | 0.03 | Why? |
| Neovascularization, Pathologic | 1 | 2017 | 305 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2017 | 1115 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2021 | 1425 | 0.03 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.03 | Why? |
| Angiogenesis Inhibitors | 1 | 2017 | 395 | 0.03 | Why? |
| Intersectoral Collaboration | 1 | 2020 | 1065 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Drug Interactions | 1 | 2019 | 1653 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Immunoenzyme Techniques | 1 | 2013 | 448 | 0.03 | Why? |
| Ventricular Function, Left | 1 | 2019 | 1555 | 0.03 | Why? |
| Antibodies | 1 | 2017 | 846 | 0.03 | Why? |
| Patient Education as Topic | 1 | 2020 | 1476 | 0.03 | Why? |
| Hand Hygiene | 1 | 2020 | 1493 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2019 | 3776 | 0.02 | Why? |
| Stroke Volume | 1 | 2019 | 2153 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Resource Allocation | 1 | 2020 | 1771 | 0.02 | Why? |
| Surveys and Questionnaires | 3 | 2021 | 43792 | 0.02 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.02 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.02 | Why? |
| Paclitaxel | 1 | 2006 | 124 | 0.02 | Why? |
| Pregnancy | 2 | 2019 | 23879 | 0.02 | Why? |
| Deoxycytidine | 1 | 2006 | 116 | 0.02 | Why? |
| Palliative Care | 1 | 2021 | 2665 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Colorectal Neoplasms | 1 | 2017 | 1884 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.02 | Why? |
| Internet | 1 | 2021 | 6204 | 0.02 | Why? |
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 372 | 0.01 | Why? |
| United States | 2 | 2021 | 46150 | 0.01 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Phosphorylation | 1 | 2005 | 1060 | 0.01 | Why? |
| Registries | 1 | 2021 | 12327 | 0.01 | Why? |
| Treatment Failure | 1 | 2006 | 2106 | 0.01 | Why? |
| Attitude of Health Personnel | 1 | 2018 | 4741 | 0.01 | Why? |
| Postoperative Complications | 1 | 2019 | 5861 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Drug Administration Schedule | 1 | 2006 | 2324 | 0.01 | Why? |
| Male | 5 | 2021 | 367725 | 0.01 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.01 | Why? |
| Lymph Nodes | 1 | 2005 | 1060 | 0.01 | Why? |
| Retrospective Studies | 2 | 2019 | 105322 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.01 | Why? |
| Adolescent | 1 | 2019 | 86841 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2018 | 88759 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |